Processing your request

please wait...

Case Page


Case Status:    DISMISSED    
On or around 02/03/2020 (Notice of voluntarily dismissal)

Filing Date: November 15, 2019

According to the Complaint, Proteon Therapeutics, Inc. focuses on improving the health of patients with kidney and vascular diseases through the development of novel, first-in-class therapeutics.

This action stems from a proposed transaction announced on September 23, 2019, pursuant to which Proteon Therapeutics, Inc. will merge with ArTara Therapeutics, Inc.

On September 23, 2019, Proteon’s Board of Directors caused the Company to enter into an agreement and plan of merger with ArTara. Pursuant to the terms of the Merger Agreement, each share of ArTara common stock will be converted into the right to receive Proteon shares such that, following the consummation of the Proposed Transaction, ArTara stockholders will own approximately 90% of the combined company, while stockholders of Proteon will own only approximately 10%.

On November 7, 2019, Defendants filed a Form S-4 Registration Statement with the United States Securities and Exchange Commission, which recommends that Proteon’s stockholders vote to approve the Proposed Transaction. The Complaint alleges that the Registration Statement omits material information with respect to the Proposed Transaction, which renders the Registration Statement false and misleading.

This case was voluntarily dismissed on February 3, 2020.


Sector: Healthcare
Industry: Biotechnology & Drugs
Headquarters: United States


Ticker Symbol: PRTO
Company Market: NASDAQ
Market Status: Public (Listed)

About the Company & Securities Data

"Company" information provides the industry and sector classification and headquarters state for the primary company-defendant in the litigation. In general, "Securities" information provides the ticker symbol, market, and market status for the underlying securities at issue in the litigation.

In most cases, the primary company-defendant actually issued the securities that are the subject of the litigation, and the securities information and company information relate to the same entity. In a small subset of cases, however, the primary company-defendant is not the issuer (for example, cases against third party brokers/dealers), and the securities information and company information do not relate to the same entity.
COURT: D. Delaware
DOCKET #: 19-CV-02143
JUDGE: Hon. Maryellen Noreika
DATE FILED: 11/15/2019
CLASS PERIOD END: 11/15/2019
  1. Rigrodsky & Long, P.A. (Wilmington)
  2. RM Law, P.C. (Berwyn)
No Document Title Filing Date
—Reference Complaint Complaint Related Data is not available
—Related District Court Filings Data is not available